Cancer Research Targets Protein Translation and Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fecci, P. E.
Right arrow Articles by Sampson, J. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fecci, P. E.
Right arrow Articles by Sampson, J. H.
[Cancer Research 66, 3294-3302, March 15, 2006]
© 2006 American Association for Cancer Research

Immunology

Increased Regulatory T-Cell Fraction Amidst a Diminished CD4 Compartment Explains Cellular Immune Defects in Patients with Malignant Glioma

Peter E. Fecci1,2, Duane A. Mitchell1, John F. Whitesides3, Weihua Xie1, Allan H. Friedman1, Gary E. Archer1, James E. Herndon, II4, Darell D. Bigner2, Glenn Dranoff5 and John H. Sampson1,2

1 Division of Neurosurgery, Departments of Surgery, 2 Pathology, 3 Medicine, and 4 Biostatistics and Bioinformatics, Duke University Medical Center, Durham, North Carolina; and 5 Department of Medical Oncology, Dana-Farber Cancer Institute, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts

Requests for reprints: John H. Sampson, Division of Neurosurgery, Department of Surgery, Duke University Medical Center, 221 Sands Research Building, Durham, NC 27710. Phone: 919-684-9041; Fax: 919-684-9045; E-mail: samps001{at}mc.duke.edu.

Immunosuppression is frequently associated with malignancy and is particularly severe in patients with malignant glioma. Anergy and counterproductive shifts toward TH2 cytokine production are long-recognized T-cell defects in these patients whose etiology has remained elusive for >30 years. We show here that absolute counts of both CD4+ T cells and CD4+CD25+FOXP3+CD45RO+ T cells (Tregs) are greatly diminished in patients with malignant glioma, but Tregs frequently represent an increased fraction of the remaining CD4 compartment. This increased Treg fraction, despite reduced counts, correlates with and is sufficient to elicit the characteristic manifestations of impaired patient T-cell responsiveness in vitro. Furthermore, Treg removal eradicates T-cell proliferative defects and reverses TH2 cytokine shifts, allowing T cells from patients with malignant glioma to function in vitro at levels equivalent to those of normal, healthy controls. Such restored immune function may give license to physiologic antiglioma activity, as in vivo, Treg depletion proves permissive for spontaneous tumor rejection in a murine model of established intracranial glioma. These findings dramatically alter our understanding of depressed cellular immune function in patients with malignant glioma and advance a role for Tregs in facilitating tumor immune evasion in the central nervous system. (Cancer Res 2006; 66(6): 3294-302)




This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
R. Ueda, M. Fujita, X. Zhu, K. Sasaki, E. R. Kastenhuber, G. Kohanbash, H. A. McDonald, J. Harper, S. Lonning, and H. Okada
Systemic Inhibition of Transforming Growth Factor-{beta} in Glioma-Bearing Mice Improves the Therapeutic Efficacy of Glioma-Associated Antigen Peptide Vaccines
Clin. Cancer Res., November 1, 2009; 15(21): 6551 - 6559.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
U. Petrausch, S. M. Jensen, C. Twitty, C. H. Poehlein, D. P. Haley, E. B. Walker, and B. A. Fox
Disruption of TGF-{beta} Signaling Prevents the Generation of Tumor-Sensitized Regulatory T Cells and Facilitates Therapeutic Antitumor Immunity
J. Immunol., September 15, 2009; 183(6): 3682 - 3689.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
C. Barcia Jr, A. Gomez, J. M. Gallego-Sanchez, A. Perez-Valles, M. G. Castro, P. R. Lowenstein, C. Barcia Sr, and M.-T. Herrero
Infiltrating CTLs in Human Glioblastoma Establish Immunological Synapses with Tumorigenic Cells
Am. J. Pathol., August 1, 2009; 175(2): 786 - 798.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
M. W. Graner, O. Alzate, A. M. Dechkovskaia, J. D. Keene, J. H. Sampson, D. A. Mitchell, and D. D. Bigner
Proteomic and immunologic analyses of brain tumor exosomes
FASEB J, May 1, 2009; 23(5): 1541 - 1557.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. M. Wiesner, S. A. Decker, J. D. Larson, K. Ericson, C. Forster, J. L. Gallardo, C. Long, Z. L. Demorest, E. A. Zamora, W. C. Low, et al.
De novo Induction of Genetically Engineered Brain Tumors in Mice Using Plasmid DNA
Cancer Res., January 15, 2009; 69(2): 431 - 439.
[Abstract] [Full Text] [PDF]

Home page
 Neuro Oncol DukeHome page
J. F.M. Jacobs, A. J. Idema, K. F. Bol, S. Nierkens, O. M. Grauer, P. Wesseling, J. A. Grotenhuis, P. M. Hoogerbrugge, I. J. M. de Vries, and G. J. Adema
Regulatory T cells and the PD-L1/PD-1 pathway mediate immune suppression in malignant human brain tumors
Neuro-oncol, January 1, 2009; 11(4): 394 - 402.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L.-Y. Kong, M. K. Abou-Ghazal, J. Wei, A. Chakraborty, W. Sun, W. Qiao, G. N. Fuller, I. Fokt, E. A. Grimm, R. J. Schmittling, et al.
A Novel Inhibitor of Signal Transducers And Activators Of Transcription 3 Activation Is Efficacious Against Established Central Nervous System Melanoma and Inhibits Regulatory T Cells
Clin. Cancer Res., September 15, 2008; 14(18): 5759 - 5768.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. B. Heimberger, M. Abou-Ghazal, C. Reina-Ortiz, D. S. Yang, W. Sun, W. Qiao, N. Hiraoka, and G. N. Fuller
Incidence and Prognostic Impact of FoxP3+ Regulatory T Cells in Human Gliomas
Clin. Cancer Res., August 15, 2008; 14(16): 5166 - 5172.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
O. J. Finn
Cancer Immunology
N. Engl. J. Med., June 19, 2008; 358(25): 2704 - 2715.
[Full Text] [PDF]

Home page
 J. Immunol.Home page
A. Waziri, B. Killory, A. T. Ogden III, P. Canoll, R. C. E. Anderson, S. C. Kent, D. E. Anderson, and J. N. Bruce
Preferential In Situ CD4+CD56+ T Cell Activation and Expansion within Human Glioblastoma
J. Immunol., June 1, 2008; 180(11): 7673 - 7680.
[Abstract] [Full Text] [PDF]

Home page
 Neuro Oncol DukeHome page
D. A. Mitchell, W. Xie, R. Schmittling, C. Learn, A. Friedman, R. E. McLendon, and J. H. Sampson
Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma
Neuro-oncol, February 1, 2008; 10(1): 10 - 18.
[Abstract] [Full Text] [PDF]

Home page
 Neuro Oncol DukeHome page
A. B. Heimberger, W. Sun, S. F. Hussain, M. Dey, L. Crutcher, K. Aldape, M. Gilbert, S. J. Hassenbusch, R. Sawaya, B. Schmittling, et al.
Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: Case study
Neuro-oncol, February 1, 2008; 10(1): 98 - 103.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. A. Perez, M. V. Karamouzis, D. V. Skarlos, A. Ardavanis, N. N. Sotiriadou, E. G. Iliopoulou, M. L. Salagianni, G. Orphanos, C. N. Baxevanis, G. Rigatos, et al.
CD4+CD25+ Regulatory T-Cell Frequency in HER-2/neu (HER)-Positive and HER-Negative Advanced-Stage Breast Cancer Patients
Clin. Cancer Res., May 1, 2007; 13(9): 2714 - 2721.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. E. Fecci, H. Ochiai, D. A. Mitchell, P. M. Grossi, A. E. Sweeney, G. E. Archer, T. Cummings, J. P. Allison, D. D. Bigner, and J. H. Sampson
Systemic CTLA-4 Blockade Ameliorates Glioma-Induced Changes to the CD4+ T Cell Compartment without Affecting Regulatory T-Cell Function
Clin. Cancer Res., April 1, 2007; 13(7): 2158 - 2167.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. Vieweg, Z. Su, P. Dahm, and S. Kusmartsev
Reversal of Tumor-Mediated Immunosuppression
Clin. Cancer Res., January 15, 2007; 13(2): 727s - 732s.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. A. Learn, P. E. Fecci, R. J. Schmittling, W. Xie, I. Karikari, D. A. Mitchell, G. E. Archer, Z. Wei, H. Dressman, and J. H. Sampson
Profiling of CD4+, CD8+, and CD4+CD25+CD45RO+FoxP3+ T Cells in Patients with Malignant Glioma Reveals Differential Expression of the Immunologic Transcriptome Compared with T Cells from Healthy Volunteers
Clin. Cancer Res., December 15, 2006; 12(24): 7306 - 7315.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. E. Fecci, A. E. Sweeney, P. M. Grossi, S. K. Nair, C. A. Learn, D. A. Mitchell, X. Cui, T. J. Cummings, D. D. Bigner, E. Gilboa, et al.
Systemic Anti-CD25 Monoclonal Antibody Administration Safely Enhances Immunity in Murine Glioma without Eliminating Regulatory T Cells.
Clin. Cancer Res., July 15, 2006; 12(14): 4294 - 4305.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2006 by the American Association for Cancer Research.